Elicio Therapeutics

Elicio Therapeutics

  • Founded: 2011
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Multiple cancers
  • Drug types: ONC, INF, VAC
  • Lead product: ELI-002
  • Product link: https://elicio.com/programs/pipeline/
  • Funding: $37M C Nov 2022; $40M B Feb 2021; $33M B Oct 2019



job board

Short description:

HPV-induced cancer treatments

Drug notes:

ELI-004 Clin1 vaccine adjuvant; ELI-003 Clin0 NSCLC; ELI-011 Clin0 hematological malignancies; ELI-012 Clin0 solid tumors; ELI-005 Clin0 COVID-19; undisclosed Clin0 infectious disease; undisclosed programs Clin0 vaccine adjuvants; ELI-007 RD oncology; ELI-008 RD oncology

Long description:

Elicio Therapeutics is harnessing the immune response to develop cancer therapeutics that are delivered via the lymphatic system. Orchestration of the immune response occurs within the lymph node, a component of the lymphatic system, where immune cells are activated. Using expertise in materials science and immunology, Elicio is using their Amphiphile technology that enables them to engineer vaccines, immunotherapies and immunomodulators against aggressive cancers and also infectious diseases by targeting them to the lymph node. By targeting the therapies to the lymph node, Elicio hopes to improve the therapeutic utility. Elicio’s lead clinical program, ELI-002, uses their therapeutic cancer vaccine to treat KRAS-driven cancers.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com